Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2.

Publication date: Sep 15, 2023

Measurable levels of immunoglobulin G antibodies develop after infections with and vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These antibody levels are dynamic: due to waning, antibody levels will drop over time. During the COVID-19 pandemic, multiple models predicting infection dynamics were used by policymakers to support the planning of public health policies. Explicitly integrating antibody and waning effects into the models is crucial for reliable calculations of individual infection risk. However, only few approaches have been suggested that explicitly treat these effects. This paper presents a methodology that explicitly models antibody levels and the resulting protection against infection for individuals within an agent-based model. The model was developed in response to the complexity of different immunization sequences and types and is based on neutralization titer studies. This approach allows complex population studies with explicit antibody and waning effects. We demonstrate the usefulness of our model in two use cases.

Open Access PDF

Concepts Keywords
Antibodies Health sciences
Coronavirus Immunology
Covid Virology


Type Source Name
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH infections
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO time
disease MESH COVID-19 pandemic
disease IDO infection
disease VO immunization
disease VO titer
disease VO population

Original Article

(Visited 4 times, 1 visits today)